Literature DB >> 9799894

Further hearing loss during osteoporosis treatment with etidronate.

S Yaşil1, A Cömlekçi, A Güneri.   

Abstract

Ototoxicity is a rare and disabling complication in bisphosphonate therapy. Here we describe two patients who encountered further hearing loss during oral etidronate treatment for osteoporosis.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9799894      PMCID： PMC2360958          DOI： 10.1136/pgmj.74.872.363

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  12 in total

Review 1.  Bisphosphonates: mechanisms of action and clinical use in osteoporosis--an update.

Authors:  H Fleisch
Journal:  Horm Metab Res       Date:  1997-03       Impact factor: 2.936

Review 2.  Etiology of otospongiotic sensorineural losses.

Authors:  J R Causse; J B Causse; P Bretlau; J Uriel; J Berges; L G Chevance; G E Shambaugh; J M Bastide
Journal:  Am J Otol       Date:  1989-03

3.  The effects of etidronate disodium on progressive hearing loss from otosclerosis.

Authors:  D W Kennedy; M E Hoffer; M Holliday
Journal:  Otolaryngol Head Neck Surg       Date:  1993-09       Impact factor: 3.497

Review 4.  The therapeutic use of bisphosphonates.

Authors:  J E Compston
Journal:  BMJ       Date:  1994-09-17

Review 5.  Etiopathogenesis of otosclerosis: a hypothesis.

Authors:  T J Yoo
Journal:  Ann Otol Rhinol Laryngol       Date:  1984 Jan-Feb       Impact factor: 1.547

6.  Clinical experience with the use of two diphosphonates in the treatment of Paget's disease.

Authors:  P Dewis; B K Prasad; D C Anderson; S Willets
Journal:  Ann Rheum Dis       Date:  1985-01       Impact factor: 19.103

7.  Ototoxicity associated with intravenous bisphosphonate administration.

Authors:  I R Reid; D A Mills; D J Wattie
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

8.  The detrimental effect of aminohydroxypropylidene bisphosphonate (APD) in otospongiosis.

Authors:  L J Boumans; R M Poublon
Journal:  Eur Arch Otorhinolaryngol       Date:  1991       Impact factor: 2.503

9.  Otosclerotic involvement of the cochlea: a histologic and audiologic study.

Authors:  D R Elonka; E L Applebaum
Journal:  Otolaryngol Head Neck Surg       Date:  1981 Mar-Apr       Impact factor: 3.497

10.  Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.

Authors:  I R Reid; D J Wattie; M C Evans; G D Gamble; J P Stapleton; J Cornish
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958
View more
  3 in total

1.  Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.

Authors:  Alicia M Quesnel; Margaret Seton; Saumil N Merchant; Christopher Halpin; Michael J McKenna
Journal:  Otol Neurotol       Date:  2012-10       Impact factor: 2.311

Review 2.  Perspectives of pharmacological treatment in otosclerosis.

Authors:  Balázs Liktor; Zoltán Szekanecz; Tamás József Batta; István Sziklai; Tamás Karosi
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-29       Impact factor: 2.503

Review 3.  Bisphosphonate therapy in otosclerosis: A scoping review.

Authors:  René E Zimmerer; Robert E Africa; Zack K Westenhaver; Brian J McKinnon
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-01-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.